Bank Julius Baer & Co. Ltd Zurich Reduces Stock Position in Gilead Sciences, Inc. $GILD

Bank Julius Baer & Co. Ltd Zurich trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,871 shares of the biopharmaceutical company’s stock after selling 1,901 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Gilead Sciences were worth $1,205,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Activest Wealth Management lifted its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter worth $27,000. Putney Financial Group LLC lifted its position in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Finally, Colonial Trust Advisors boosted its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $126.64 on Friday. The firm’s fifty day simple moving average is $118.48 and its two-hundred day simple moving average is $113.65. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The company has a market cap of $157.12 billion, a price-to-earnings ratio of 25.23, a PEG ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Morgan Stanley lifted their price objective on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $130.87.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the sale, the chief financial officer directly owned 154,555 shares of the company’s stock, valued at $19,354,922.65. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 125,146 shares of company stock worth $15,148,441. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.